KPMG at the 40th Annual J.P. Morgan Healthcare Conference 2022

Welcome Remarks

• Mitch Bloom, Chair, Life Sciences and Partner, Goodwin
• Kristin Pothier, Principal, National Strategy Healthcare and Life Sciences Leader, KPMG

Ignite Talk | The State of the European Biotech

• David Mardle, Partner, Goodwin
• Anne-Charlotte Rivière, Partner, Goodwin

Panel | Evolving European Biotech Landscape

This panel will address the challenges and dynamics of various clusters of biotech innovation in Europe with the UK being the leader as well as other strong centers such as Nordics. We will also discuss emerging clusters that are a couple of years behind the UK and Nordics but are the next places to be such as France and Germany and other continental parts of Europe.

• Sophie McGrath, Partner, Goodwin (Moderator)
• Jasper Bos, Ph.D., General Partner, Forbion
• Rachel Mears, Partner, Jeito Capital
• Soren Moller, Managing Partner, Novo Holdings 

Ignite Talk: Hot Topics in 2022 and Beyond in the Healthcare Regulatory Environment

• Matt Wetzel, Partner, Goodwin

Panel | An Industry in Transformation 

In recent years, we have seen several technology companies attempt to transform their businesses by adding healthcare components and developing products and apps that are regulated by the FDA. Conversely, we have also seen traditional medical technology companies develop products that enable data platforms that hold vast amounts of aggregated patient and prescriber data. As tech companies trend towards healthcare, and as healthcare companies move towards tech, this panel will explore what challenges these companies face in terms of competition, regulatory controls and government oversight.

• Kristin Pothier, Principal, National Strategy Healthcare and Life Sciences Leader, KPMG (Moderator)
• Sarah Bobulsky, VP of Commercial, Helix
• Dave Cappillo, Partner, Goodwin
• Chris Klomp, Chief Evangelist, PointClickCare

Fireside Chat | Innovation in Women’s Health and Wellbeing: Critical Legal Considerations

We are at a turning point in the transformation of healthcare, and technological innovation in the Women’s Health and Wellbeing sector has never been stronger. The industry is expected to reach $41 billion by 2027 and is experiencing a newfound interest in removing the barriers that stalled its growth for decades. The evolution of the industry raises important legal issues and regulatory challenges that must be overcome to propel the industry forward. This fireside chat will address why the sector is attracting more investment, the legal structures that must be shifted to facilitate this evolution, the role that technology is playing in transforming the space, and where technological innovation still needs to catch up to improve the lives of women everywhere. 

• Delphine O’Rourke, Partner, Goodwin (Moderator)
• Sandy Milligan, M.D., J.D., Head of Research and Development, Organon

Panel | Privacy Guardrails for the Digital Healthcare Revolution

Large-scale digital processing of sensitive personal data has powered technology that has brought treatment and support to countless patients.  From access to mental health, nutrition guidance and medicine to patient portals and support communities, and to medical research, entrepreneurs have created technology to improve and save lives. This panel will look at the data trends and technologies that are reshaping healthcare, and how companies can handle sensitive personal data fairly and transparently, respecting privacy and data protection laws and societal expectations, as well as articulate their privacy-protective stance to patients, regulators and the society at large. Our discussion will touch on the evolving global privacy landscape, including in the United States, Europe and other parts of the world, and offer participants practical guidance on privacy compliance guardrails in health tech. 

• Boris Segalis, Partner, Goodwin (Moderator)
• Lore Leitner, Partner, Goodwin
• Gordon Kessler, CAO General Counsel, AiCure

Keynote | Fireside Chat with Cerevel Therapeutics CEO, Tony Coles

• Stuart Cable, Partner, Goodwin (Moderator)
• Tony Coles, M.D., CEO and Chairperson, Cerevel Therapeutics

Ignite Talk | State of the Capital Markets

• Jack Bannister, Managing Director – Equity Capital Markets, SVB Leerink 

Panel | Accessing the Public Markets: Chart Your Own Course. 

This interactive life sciences capital markets panel will focus on the key steps for deciding which type of offering to pursue, best practices for preparing and executing a capital markets transaction, ways to mitigate litigation risk along the way, and what you can expect to encounter as a newly public company.

• Tim Lashua, Partner, Deal Advisory – Accounting Advisory Services, KPMG (Moderator)
• Jacqueline Mercier, Partner, Goodwin
• Maggie Wong, Partner, Goodwin
• Katie Wechsler, Partner, Audit, KPMG  
• Rajiv Shukla, Chairman and CEO, Alpha Healthcare ACQ Corporation
• Jack Bannister, Managing Director – Equity Capital Markets, SVB Leerink 

Fireside Chat | Stories From the Front

• Katie Wechsler, Audit Partner, KPMG (Moderator)
• Mike Byrnes, Chief Financial Officer, eFFECTOR
• Jason O’Byrne, Chief Financial Officer, Caribou Biosciences

Fireside Chat |  A Fly in the Ointment? Antitrust Expansion in Life Sciences Collaborations and Combinations

The Federal Trade Commission (FTC) and other competition agencies across the globe have increased their scrutiny of transactions in the life sciences industry. The FTC has spearheaded the formation of a Multilateral Pharmaceutical Merger Task Force to explore potentially new theories of harm and new ways to analyze the competitive effects of proposed transactions. At the same time, the industry continues to be innovative in its deal making to manage the technical, regulatory and commercial risks. This fireside chat will address the unique antitrust issues that arise when smaller innovative life sciences companies collaborate with or get acquired by big pharma, and how the new trends in antitrust scrutiny might affect such transactions. 

• Lisa Haddad, Partner, Goodwin (Moderator)
• Arman Oruc, Partner, Goodwin
• Andy Lacey, Partner, Goodwin

Fireside Chat | Approaching a New 2022: The Real Keys to Innovative Deal Making This Year

Over the last year, despite the ongoing challenges of the pandemic, the life sciences industry has seen some of its most innovative deals to date. This panel will highlight lessons learned from these deals, including the need to get creative, and discuss which tactics are here to stay.

• Kristin Pothier, Principal, National Strategy Healthcare and Life Sciences Leader, KPMG (Moderator)
• Bonnie Anderson, CEO, Veracyte